To pandemic preparedness and beyond: Accelerating novel antibody therapeutics through cross-border collaboration

Dr. Sriram Subramaniam who leads UBC’s PROGENITER program which works to bolster Canada’s pandemic preparedness by creating a suite of ready-to-deploy antibody treatments — *Dr. Sriram Subramaniam, UBC AI and Health Network member, leads UBC’s PROGENITER program which will bolster Canada’s pandemic readiness by creating a suite of ready-to-deploy antibody treatments.*

The UBC AI & Health Network congratulates Network Member Dr. Sriram Subramaniam on a new cross-border collaboration with Boston-based Alloy Therapeutics, a partnership that combines AI and structural biology to accelerate the discovery of antibody therapeutics.

Dr. Subramaniam, professor of biochemistry and molecular biology at UBC and Gobind Khorana Canada Excellence Research Chair, leads a project called Pathogen Response Optimization by GENeratIng ThErapeutics Rationally (PROGENITER), one of four federally funded research projects under Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH). PROGENITER will leverage AI-enabled drug discovery and advanced cryo-EM microscopy to create a suite of ready-to-deploy antibody treatments for existing and emerging health threats such as COVID-19 and influenza.

Integrating Alloy Therapeutics’ drug discovery technologies with AI antibody design and engineering, PROGENITER aims to bring new therapies to patients sooner.

Through collaborations like this, UBC AI & Health Network members are advancing the use of AI to drive drug discovery and strengthen Canada’s leadership in the rapidly evolving AI and health innovation landscape.

Learn more